GLUE
Monte Rosa Therapeutics, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $3.94 | $18 | +357% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $4.50 | $18 | +300% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $4.50 | $18 | +300% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $4.50 | $18 | +300% |
| Two Sigma Investments | Q4 2024(8Q snapshot) | 6Q | $8.48 | $18 | +112% |
| AQR Capital Management | Q2 2025(8Q snapshot) | 4Q | $3.87 | $18 | +365% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q4 2025 | Q1 2026 | → $18 | +28% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Monte Rosa Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 2, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-253472Jun 2, 2026
- Form 40001193125-26-251395Jun 1, 2026
- Form 40001193125-26-245728May 28, 2026
- Form 40001193125-26-239240May 26, 2026
- Form 40001193125-26-236840May 22, 2026
- Form 40001193125-26-206344May 5, 2026
- Form 40001193125-26-156981Apr 15, 2026
- Form 40001193125-26-151254Apr 10, 2026
- Form 40001193125-26-145545Apr 7, 2026
- Form 40001193125-26-094296Mar 5, 2026
- Form 40001193125-26-091733Mar 4, 2026
- Form 40001193125-26-085677Mar 2, 2026
- Form 40001193125-26-066955Feb 24, 2026
- Form 40001193125-26-008902Jan 9, 2026
- Form 40001193125-26-002406Jan 5, 2026
Fundamentals
XBRL · Monte Rosa Therapeutics, Inc.Annual figures sourced directly from Monte Rosa Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Monte Rosa Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 29, 2026
- 10-KAnnual reportMar 17, 2026
- 8-KMaterial eventMar 17, 2026
- 8-KMaterial eventFeb 10, 2026
- 8-KMaterial eventJan 9, 2026
- 8-KMaterial eventJan 7, 2026
- 8-KMaterial eventJan 7, 2026
- 8-KMaterial eventDec 16, 2025
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 8-KMaterial eventSep 15, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q2 2026 | open | $19 | $18 | -4% |
| D.E. Shaw | Q4 2025 | open | $14 | $18 | +25% |
| Point72 Asset Management | Q4 2025 | Q1 2026 | $14 | $18 | +28% |
| Citadel Advisors | Q3 2025 | open | $4.35 | $18 | +314% |
| AQR Capital Management | Q2 2025 | open | $3.87 | $18 | +365% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $6.78 | $3.87 | -43% |
| Two Sigma Investments | Q4 2024 | open | $8.48 | $18 | +112% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $4.50 | $3.87 | -14% |
| D.E. Shaw | Q3 2024 | Q2 2025 | $4.50 | $3.87 | -14% |
| Millennium Management | Q3 2024 | open | $4.50 | $18 | +300% |
| Renaissance Technologies | Q3 2024 | Q1 2026 | $3.94 | $19 | +370% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.